Will immunotherapy open a new era in cancer treatment?

From 21 to 22 November, 2013, in Ufa – the capital of Bashkortostan Republic, the Eurasian Anticancer Conference "Prediction & Prevention in Modern Oncology" is being held. The leading oncologists and scientists from many countries are participating in the conference. Representatives from the Latvian Virotherapy Center and Latvian scientists will present a report and conduct a round-table discussion about Virotherapy with RIGVIR and its role in the treatment of oncological diseases and immunity boosting. 

The virotherapy medicine with antitumour effect, immunomodulator RIGVIR, was created in Latvia; clinical experience for more than 40 years; registered in the State Agency of Medicines of the Republic of Latvia; available for the treatment of oncological diseases in clinics and doctors' private practices.

RIGVIR® discoverer, researcher, Professor, Dr.med.habil. Aina Muceniece has been awarded the Latvian order Cross of Acknowledgement for special merits in favour of Latvia.